BioSpace News Archive

25 million doses includes 10 million doses of mRNA-1273 to begin delivery in 2021 and 15 million doses of updated variant booster candidate to begin delivery in 2022

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the virtual 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. ET.

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been awarded a new $2.7 million research grant award from the National Institutes of Health (NIH).

TMS-007 has the potential to be a next generation thrombolytic with an improved benefit-risk profile Acute ischemic stroke is caused by a blockage of blood supply to the brain, and current thrombolytics are limited in use due in part to increased risks of bleeding Phase 2a study demonstrated positive impacts on blood vessel reopening and patient functional recovery with no incidence of symptomatic intracranial hemorrhage

Crescita Therapeutics Inc., a growth-oriented, innovation-driven Canadian commercial dermatology company, announced the voting results from its 2021 Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Québec.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced that Jerry Durso, President and Chief Executive Officer of Intercept, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 4:50 p.m. ET.

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announced that it has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.

Two-year grant awarded by the Hong Kong Government’s Innovation and Technology Commission is funding the development of new bispecific antibodies targeting NRP2

AbbVie (NYSE: ABBV) will participate in the RBC Capital Markets Global Healthcare Conference on Tuesday, May 18, 2021 .

NS Pharma, Inc., a wholly owned subsidiary of Nippon Shinyaku Co., Ltd., announced that new, long-term efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO® injection will be presented at the PPMD 2021 Annual Conference being held virtually from June 23-26.